Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.22 -4.4%	$0.51	$0.22 ▼ $1.65	$56.29M	2.52	1.71 million shs	1.88 million shs
ALGS Aligos Therapeutics	$9.66	$19.72	$6.76 ▼ $46.80	$59.06M	2.52	174,493 shs	98,721 shs
BFRG Bullfrog AI	$1.81 -4.7%	$2.38	$1.43 ▼ $4.84	$17.04M	0.32	319,597 shs	64,723 shs
IGMS IGM Biosciences	$1.28 +4.1%	$1.41	$1.15 ▼ $22.50	$76.51M	0.37	338,038 shs	115,447 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-7.96%	-48.76%	-58.33%	-59.47%	-84.86%
ALGS Aligos Therapeutics	-10.14%	-17.79%	-45.79%	-77.73%	-62.12%
BFRG Bullfrog AI	-8.65%	+5.56%	-28.84%	-17.03%	-45.56%
IGMS IGM Biosciences	-2.38%	-3.15%	-8.21%	-81.50%	-85.83%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.6519 of 5 stars	3.4	5.0	0.0	2.2	1.7	0.0
ALGS Aligos Therapeutics	4.0119 of 5 stars	3.5	2.0	4.8	1.9	1.7	0.6
BFRG Bullfrog AI	1.3965 of 5 stars	0.0	5.0	0.0	3.4	1.7	0.0
IGMS IGM Biosciences	4.8489 of 5 stars	4.0	4.0	4.6	3.5	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.80	Moderate Buy	$1.93	777.27% Upside
ALGS Aligos Therapeutics	3.00	Buy	$70.00	624.64% Upside
BFRG Bullfrog AI	0.00	N/A	N/A	N/A
IGMS IGM Biosciences	1.90	Reduce	$5.50	329.69% Upside

Current Analyst Ratings Breakdown

Latest BFRG, IGMS, ALGS, and ADAP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/26/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.75
3/21/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $1.50
3/21/2025	ADAP Adaptimmune Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$3.15 ➝ $1.40
3/11/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
1/13/2025	IGMS IGM Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral
1/10/2025	IGMS IGM Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$48.00 ➝ $2.00
1/10/2025	IGMS IGM Biosciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$12.00 ➝ $2.00
1/10/2025	IGMS IGM Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$22.00 ➝ $3.00
1/10/2025	IGMS IGM Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$12.00 ➝ $2.00
1/10/2025	IGMS IGM Biosciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$27.00 ➝ $2.50
1/10/2025	IGMS IGM Biosciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$20.00 ➝ $1.50

(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$175.04M	0.32	N/A	N/A	$0.17 per share	1.29
ALGS Aligos Therapeutics	$3.95M	14.97	N/A	N/A	$30.65 per share	0.32
BFRG Bullfrog AI	$60K	284.02	N/A	N/A	$0.43 per share	4.21
IGMS IGM Biosciences	$2.68M	28.56	N/A	N/A	$3.46 per share	0.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.22	N/A	N/A	N/A	-25.43%	-74.15%	-15.09%	5/13/2025 (Estimated)
ALGS Aligos Therapeutics	-$87.68M	-$20.90	N/A	N/A	N/A	-1,283.19%	-114.34%	-64.58%	5/6/2025 (Estimated)
BFRG Bullfrog AI	-$5.36M	-$0.86	N/A	∞	N/A	N/A	-141.39%	-124.63%	4/4/2025 (Estimated)
IGMS IGM Biosciences	-$246.42M	-$3.24	N/A	N/A	N/A	-7,534.03%	-155.42%	-61.04%	5/6/2025 (Estimated)

Latest BFRG, IGMS, ALGS, and ADAP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million
3/14/2025	Q4 2024	BFRG Bullfrog AI	N/A	-$0.18	N/A	-$0.18	N/A	N/A
3/10/2025	Q4 2024	ALGS Aligos Therapeutics	-$2.63	-$13.08	-$10.45	-$13.08	$0.43 million	$0.63 million
3/6/2025	Q4 2024	IGMS IGM Biosciences	-$0.74	-$0.61	+$0.13	-$0.61	$0.39 million	$0.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
BFRG Bullfrog AI	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
ALGS Aligos Therapeutics	N/A	3.81	3.81
BFRG Bullfrog AI	N/A	5.90	5.90
IGMS IGM Biosciences	N/A	5.22	5.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
ALGS Aligos Therapeutics	60.43%
BFRG Bullfrog AI	0.96%
IGMS IGM Biosciences	42.79%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
ALGS Aligos Therapeutics	8.75%
BFRG Bullfrog AI	33.90%
IGMS IGM Biosciences	57.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	255.88 million	224.05 million	Optionable
ALGS Aligos Therapeutics	90	6.11 million	3.27 million	No Data
BFRG Bullfrog AI	4	9.42 million	5.76 million	Not Optionable
IGMS IGM Biosciences	190	59.78 million	25.57 million	Optionable

BFRG, IGMS, ALGS, and ADAP Headlines

Recent News About These Companies

IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of "Reduce" from Analysts

March 25 at 4:40 AM | marketbeat.com

IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9% - Here's Why

March 25 at 1:39 AM | marketbeat.com

IGM Biosciences (IGMS) Gets a Hold from RBC Capital

March 7, 2025 | markets.businessinsider.com

Morgan Stanley Sticks to Their Sell Rating for IGM Biosciences (IGMS)

March 7, 2025 | markets.businessinsider.com

IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of "Reduce" from Brokerages

February 28, 2025 | marketbeat.com

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

February 27, 2025 | zacks.com

IGM Biosciences (IGMS) Projected to Post Quarterly Earnings on Thursday

February 27, 2025 | marketbeat.com

Igm Biosciences

February 16, 2025 | forbes.com

IGM Biosciences (IGMS) Receives a Hold from Bank of America Securities

February 13, 2025 | markets.businessinsider.com

Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround

February 5, 2025 | zacks.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

February 1, 2025 | accessnewswire.com

IGM Biosciences stock plunges to 52-week low of $1.59

January 28, 2025 | msn.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

January 28, 2025 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

January 26, 2025 | accessnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

January 24, 2025 | accessnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

January 22, 2025 | accessnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

January 18, 2025 | accessnewswire.com

Igm biosciences principal accounting officer sells $1,907 in stock

January 17, 2025 | msn.com

IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation

January 17, 2025 | accessnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

January 16, 2025 | accessnewswire.com

Bank of America Securities Sticks to Their Hold Rating for IGM Biosciences (IGMS)

January 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRG, IGMS, ALGS, and ADAP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.22 -0.01 (-4.39%)

Closing price 04:00 PM Eastern

Extended Trading

$0.23 +0.01 (+6.36%)

As of 07:34 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Aligos Therapeutics NASDAQ:ALGS

$9.66 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$9.48 -0.18 (-1.86%)

As of 06:16 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Bullfrog AI NASDAQ:BFRG

$1.81 -0.09 (-4.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 +0.05 (+3.04%)

As of 07:33 PM Eastern

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

IGM Biosciences NASDAQ:IGMS

$1.28 +0.05 (+4.07%)

Closing price 04:00 PM Eastern

Extended Trading

$1.24 -0.04 (-3.52%)

As of 07:38 PM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time